Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R46 | P59540 | 10/20 | 0.49 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.37 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10307305 | 0.84 | TAS2R46 (0.62) | TAS2R46TAS2R31TAS2R10RECQLPTPN1 | |
| SCHEMBL30834897 | 0.84 | TAS2R46 (0.62) | TAS2R46TAS2R31TAS2R10RECQLPTPN1 | |
| SCHEMBL1753395 | 0.84 | TAS2R46 (0.62) | TAS2R46TAS2R31TAS2R10RECQLPTPN1 | |
| SCHEMBL10307313 | 0.77 | TAS2R46 (0.61) | TAS2R46TAS2R31TAS2R10RECQLMEN1 | |
| SCHEMBL1753501 | 0.77 | TAS2R46 (0.61) | TAS2R46TAS2R31TAS2R10RECQLMEN1 | |
| SCHEMBL27183431 | 0.74 | TAS2R46 (0.59) | TAS2R46TAS2R31TAS2R10RECQLMEN1 | |
| SCHEMBL27183427 | 0.74 | TAS2R46 (0.59) | TAS2R46TAS2R31TAS2R10RECQLMEN1 | |
| SCHEMBL27183429 | 0.74 | TAS2R46 (0.59) | TAS2R46TAS2R31TAS2R10RECQLMEN1 | |
| SCHEMBL30462356 | 0.67 | TAS2R46 (1.00) | TAS2R46TAS2R31TAS2R10RECQLMEN1 | |
| Dihydro Costunolide SCHEMBL31238153 | 0.62 | TAS2R46 (1.00) | TAS2R46TAS2R31TAS2R10RECQLPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | ANJI PHARMA (US) LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2019-02-07 | — | — | US | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10610500-B2 | Chemosensory receptor ligand-based therapies | TAS1R2, TAS2R1, GPR119 | TAS2R46 23/4885TAS2R31 21/4885TAS2R10 7/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TAS2R46 23/4885TAS2R31 21/4885TAS2R10 7/4885 |
| US-20190038576-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | TAS2R46 23/4885TAS2R31 21/4885TAS2R10 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.